Bavarian Nordic — Marts 2022
-
Det er altså mærkeligt at Bavarian ikke stiger med det snak der er om risikoen for Kemisk krigsførsel i Ukraine - Bavarian Nordic er den eneste som kan levere Kopper vaccine som er en af de mest frygtet samt de har også en del til Ebola samt de har arbejdet med andre ting - kursmål er godt gns 400 jf. Bloomberg..
-
Video - TA på Novo Nordisk
- Zealand Pharma
- Genmab
- Bavarian https://www.proinvestor.com/boards/102346/4-efterspurgte-danske-aktier-med-TA-FA
-
-
Kort video: Jeg orienterer om overflytningen af ProInvestor til en ny platform. Der lys forude. :−) I disse tider med krig, rentestigninger osv. kan det være svært at navigere som aktieinvestor. Jeg guider til gode input ift. situationen i Ukraine og Rusland og inspiration til, hvad man kan gøre med sin portefølje i en svær tid, med Hans-Henrik Nielsen fra Markettimer. https://www.proinvestor.com/boards/102348
-
SUPPORT-ABONNEMENT - Støt Proinvestor.com: https://www.proinvestor.com/donation
-
@Enkommentar1: det er nok fordi de kemiske våben, som man frygter der bruges i Ukraine er nok nervegas eller giftgas… altså Zyklon-B, sennepsgas, klorgas og den type ulovlige våben…
-
Dejligt, håber mine Expression kommer tilbage i kurs 60 nu
-
NBI ved at bunde ud https://www.proinvestor.com/boards/102420/NBI-ved-at-bunde-ud
-
(Bava - Euroinvestor)
-
helt grotesk ift analytikeres holdning
-
Måske der alligevel bliver stærkt brug for Bavarians Covid vaccine, den er vel mere effektiv mod nye varianter end eksisterende vacciner
https://ing.dk/artikel/corona-varianter-stigende-grad-begyndt-at-udveksle-gener-lidt-gyser-255562? -
Ja hvis vi bare vidste om deres vaccine virker på Omikron variationen.
-
Carlsberg exit, Tesla stigning og bund i biotek? https://www.proinvestor.com/boards/102571
-
RSV Vaccine Candidate From BAVA Approaching the Starting Gate:
Compared to other development programs, the BAVA RSV vaccine (MVA-BN RSV) is the only RSV vaccine incorporating five different RSV antigens to stimulate a broad immune response against RSV subtypes (A and B) thus mimicking the immune response observed following a natural reaction to an RSV infection.
Ref to attached overview - despite the race of getting first to market there is clearly room for a lot of RSV development programs ()
-
() and BAVA is amongst the first out of the starting gate.
The global RSV therapeutics market was estimated at USD$ 1,111.3 million in 2019 and is projected to exceed USD$ 4,000 million by 2027. Considering BAVA has secured a partnership agreement for China and Asia shareholders are waiting patiently.
Good luck to all the shareholders!
Source: NFID - https://www.nfid.org/wp-content/uploads/2022/01/NFID-RSV-Call-to-Action.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind